Text: H01603 Text: H01605 Text: H01600 - H01699 Text: H Index Bills and Amendments: General Index Bill History: General Index
PAG LIN 1 1 Amend House File 715 as follows: 1 2 #1. Page 15, by striking lines 21 and 22 and 1 3 inserting the following: 1 4 "1. a. The department shall continue prospective 1 5 drug utilization review and may establish drug 1 6 surveillance prior authorization under the medical 1 7 assistance program. The department shall also conduct 1 8 a prior authorization cost-effectiveness review study 1 9 and shall not include in the study any individual 1 10 currently or previously utilized for a similar study 1 11 by the department. 1 12 b. The prospective drug utilization review and 1 13 prior authorization review studies shall include, but 1 14 are not limited to, all of the following: 1 15 (1) The net cost of the generic substitution and 1 16 brand-name drugs denied under prior authorization, 1 17 including the effect of rebates. 1 18 (2) The costs attributed to cost-shifting to more 1 19 expensive treatment regimens, including additional 1 20 physician visits, emergency room visits, 1 21 hospitalization, and nursing home placements. 1 22 (3) The cost of prescribing mandates, such as 1 23 requiring two failures of generic drug treatment 1 24 before allowing prescribing of a brand-name 1 25 alternative. 1 26 (4) Outcomes measures of cost-effectiveness and 1 27 comparison of the two approaches. 1 28 (5) Administrative costs and comparison of the two 1 29 approaches. 1 30 c. Beginning April 1, 1998, the department shall 1 31 remove from the categories of prescription drugs, for 1 32 which prior authorization is currently necessary, all 1 33 of the following for which the comparative drug usage 1 34 studies establish that prospective drug utilization 1 35 review is at least as cost-effective as prior 1 36 authorization: 1 37 (1) Nonsedating antihistamines. 1 38 (2) Histamine H2-receptor antagonists. 1 39 (3) Cephalexin hydrochloride monohydrate 1 40 prescriptions. 1 41 (4) Single-source nonsteroidal anti-inflammatory 1 42 drugs. 1 43 (5) Single-source benzodiazepines. 1 44 (6) Topical acne products. 1 45 (7) Proton pump inhibitors. 1 46 d. The department may adopt emergency rules to 1 47 implement this subsection." 1 48 1 49 1 50 2 1 BLODGETT of Cerro Gordo 2 2 2 3 2 4 2 5 HANSEN of Pottawattamie 2 6 HF 715.702 77 2 7 pf/sc/28
Text: H01603 Text: H01605 Text: H01600 - H01699 Text: H Index Bills and Amendments: General Index Bill History: General Index
© 1997 Cornell College and League of Women Voters of Iowa
Comments about this site or page? webmaster@legis.iowa.gov. Please remember that the person listed above does not vote on bills. Direct all comments concerning legislation to State Legislators.
Last update: Wed Apr 9 03:43:12 CDT 1997
URL: /DOCS/GA/77GA/Legislation/H/01600/H01604/970408.html
jhf